key: cord-0874889-7gnpw0k8
authors: Carafoli, Ernesto
title: Chloroquine and hydroxychloroquine in the prophylaxis and therapy of COVID-19 infection
date: 2020-09-30
journal: Biochem Biophys Res Commun
DOI: 10.1016/j.bbrc.2020.09.128
sha: 4369137ec17b87cf9bab115429bb0204012eec04
doc_id: 874889
cord_uid: 7gnpw0k8

At the end of last century a prominent biochemist once opened the discussion of a controversial issue in the field of Bioenergetics with the following statement: “This is a long story, that shouldn't be long, but it will take a long time to make it short”. As it happens, such a statement would apply perfectly well to the story of chloroquine (CQ) and hydroxychloroquine (HCQ) in the COVID-19 infection: it has become a veritable saga, with conflicting views that have often gone beyond the normal scientific dialectic, and with conclusions that have frequently been polluted by non scientific opinions: thus, for instance, when National Agencies have taken positions against CQ and HCQ, the move has been seen as a pro-vaccine attempt to block low cost therapy means. And it is difficult to avoid the feeling that the opposition to CQ and HCQ has in large measure been shaped not by scientific arguments, but by the fact that their use has been strongly endorsed by National leaders whose popularity among Western intellectuals is extremely low. The role of the two drugs in the COVID-19 infection thus deserves an objective analysis solely based on scientific facts. This contribution will attempt to produce it.

2 soldiers of the Second World War treated with antimalarials. Its use was thus successfully extended to the treatment of other autoimmune disease like systemic lupus erythematosus, Siogren's syndrome, rheumatoid arthritis, and sarcoidosis (7) . Outside malaria, the spectrum of possible activities of CQ, and of its derivative HCQ, has been further enlarged by the finding that their biochemical effects were associated with the inhibition of the inflammatory response commonly observed in bacterial and viral infections: CQ inhibits the production/release of tumor necrosis factor alpha (TNF alpha) and of interleukin-6, which are responsible for the pathological symptomatology of viral diseases. Thus, at the turn of last century, CQ was repurposed against HIV and other viruses (8) (9) (10) .

In their immunomodulatory/antiinflammatory effects, CQ and HCQ have multiple modes of action. Outside cells, in vitro experiments have shown that they inhibit the glycosylation of the SARS coronavirus cell surface target, the ACE2 receptor (11) . And a recent structural and molecular modelling study has identified a ganglioside binding domain in the N-terminal portion of the S-protein of COVID-19 that interacts with surface gangliosides of the host cells, facilitating contact with the ACE receptor: CQ and HCQ inhibit the interaction, and thus the penetration of the virus into the target cell (12) .

The non-protonated form of CQ and HCQ diffuses across the plasma membrane to the cytoplasm, where it is reprotonated and accumulated in the acidic intracellular organelles such as the endosomes, the trans-Golgi network, and the lysosomes , increasing their pH and thus decreasing the activity of their hydrolytic enzymes.

Early in vitro experiments had indeed shown that the pH in endosomes of macrophages increased from 4.5 to 6.5 after a few minutes of exposure to 100 uM CQ (13) . In the absence of CQ, the low internal pH mediates the fusion of the endosomal and viral membranes and thus the internationalization of the virus (14)A quantitative analysis of COVID-19 entry in Vero E6 cells exposed to 50 uM CQ or HCQ (15) has shown that , in untreated cells, after 90 minutes, 16.2 % of the internalized virions were in the early endosomes (EEs), and 34.3% had been transported to late endosomes (ELs). By contrast, in the treated cells, only 2.4 % of the virions had remained in the EEs in the case of CQ and 0.03 % in the case of HCQ , whereas 35.3 % had been transported to the ELs in the case of CQ and 29.2 % in the case of HCQ. CQ and HCQ had thus blocked the transport of the COVID-19 virions from the early endosomes to the late endosomes. Eventually,in the absence of CQ or HCQ , the virions ends up in the lysosomes, where the hydrolytic enzymes uncoat it , liberating into the cytoplasm the infectious genomic RNA which is translated into pp1a and pp1ab proteins. These two proteins are cleaved by a protease to make a total of 16 non structural proteins (nsp) (16) , some of which form the replication/transcription complex (RNA-dependent RNA polymerase). Work on several viruses has shown that the CQ-induced increase of pH blocks the uncoating activity of the lysosomal hydrolytic enzymes, thus abrogating the entire replication cycle of the virus (17) . The cartoon of Figure 2 shows the phases of the virus challenge to the target cell, from its penetration into it, to the liberation of the genomic RNA into the cytoplasm, to its process of replication and de novo assembly, to its final exit from the cell to propagate the infection. For reasons of completion, it could be mentioned that the cell penetration of COVID-19 could also occur via a pH independent pathway: whereas in most cell lines the penetration of the virus is promoted by the J o u r n a l P r e -p r o o f activation of the S-protein by pH dependent endosomal proteases, in other cell lines, e.g., airway epithaeial cells , a pH-independent protease (TMPRSS2) activates instead the S-protein.

In a number of viruses, from HIV, to Dengue, to herpes simplex, to human coronaviruses like MERS, CQ has also been shown to interfere with the post-translational modification of viral proteins mediated by proteases and glycosyltransferases in the endoplasmic reticulum and trans-Golgi network of the host cell (18) (19) (20) Finally, CQ and HCQ have been found to reduce the production of pro-inflammatory cytokines like IL-1, IL-6, TNF, and IFNgamma by several cell types,, e.g., mononuclear cells (21) .

One last aspects of the molecular /cellular effects of CQ and HCQ must be mentioned at the end of this chapter on the mechanisms of action of the two drugs: their possible negative side effects. CQ and HCQ have a well studied toxicity profile, and the safety of CQ use has been demonstrated by the decades of its administration to humans in malaria-endemic countries. They are now widely used to treat autoimmune diseases, and, at the dosages that are routinely used, their safety profile is considered very good. Occasionally, however, adverse side effects have been described (22) , and it is important to mention them because they have been greatly emphasized in the descriptions and discussions of the results of therapy attempts, including international trials, of COVID-19 using CQ and, especially, HCQ. The most important adverse side effects that have been described are cardiac rhythm disorders, i.e., a prolongation of the electrocardiographic Q-T interval (23) , and the development of retinopathy (24) : which is more commonly associated with CQ than with HCQ, and depends on the cumulative dose more than on the daily dose. The retinal damage is attributed to the disruption of the lysosomal degradation process in photoreceptor outer segments.

As mentioned above, the arrival of CQ (and HCQ) on the scene of antiretroviralviral therapy was sparked by their beneficial effects on the inflammatory response commonly observed in bacterial, fungal, and even viral diseases, but, especially, by the need for treatments less expensive than those under study for a number of diseases: at the end of last century the most important, and thus the prime target, was the HIV infection (25) (26) . However, in the following years the antiviral efficiency of CQ was also tested on a number of other viruses, including the SARS coronavirus. Eventually, a study by Wang The French study had a number of serious shortcomings that later commentaries have convincingly discussed in detail (29) (30) , but it nevertheless immediately attracted worldwide attention. Its findings were rapidly disseminated by the press and amplified by the social media, initiating a period of great popularity of HCQ.

Government and institutional leaders endorsed it, to the point that it was proclaimed to be "game changer" in the fight against COVID-19. These overtones, and the enthusiastic endorsements by political Leaders whose popularity indexes were abysmally low among Western opinion makers, were clearly damaging: they were instrumental in generating a feeeling of annoyance against CQ and HCQ , and the ideological backlash that soon hit them. However, it wasn't only Governments and leaders who had so promptly and generally accepted CQ and HCQ: Hospitals and doctors in general, and also National Agencies, started administering and recommending HCQ . As an example, it may be interesting to quote here a document of the Italian Federation of Family Doctors , that included HCQ in the treatment of certified, and even only suspected, cases of COVID-19 infection. Adverse feelings were nevertheless beginning to surface: for instance, the document of the Italian Family Doctors had an appendix that contained a long list of conditions, that in effect embraced most human pathologies, that were incompatible with the HCQ therapy. In hindsight, it was an indirect indication of the mounting wave of alarming warnings on the dangers of the HCQ therapy. And so, in a short while CQ and HCQ became the subjects of a dispute that was gradually corrupted by non-scientific arguments that divided the scientific community in a way similar to that of supporters of competing sports teams. From the scientific angle, the unpleasant aspect of the dispute was the rush to publish as rapidly as possible results that would either prove , or diprove, the efficacy of CQ or HCQ, and/or their safety or their dangers. The standard in the generation and interpretation of the results rapidly became increasingly relaxed, with the result that a lot of bad science inundated the literature from both sides. The most striking example of this sort of corrupted scientific behaviour undoubtedly was the first large scale international trial on HCQ, that had at long last been sponsored by the WHO to provide the final answer to the question of the efficacy of CQ and HCQ in the fight against COVID-19. The trial had involved 96.000 COVID-19 patients in 671 hospitals around the world, and the article that described the results had been submitted at the end of May, 2020 to the leading Journal Lancet.

The article had been promptly accepted: It had found that the mortality and the cardiac complications were higher in the patients treated with the two drugs that in the untreated controls. (31) : as a result, the WHO immediately interrupted the trial, proclaming the inefficacy, and even the dangers, of CQ and HCQ therapy.

National Agencies that had previously recommended the use of CQ and HCQ immediately followed suit, and cancelled the recommendation. Was it the end of the story ? Not at all, because the findings in the Lancet paper, and the decision of WHO, started a veritable immediate revolt in the scientific community: 182 specialists, many of them actually "opponents" of HCQ, literally cut the Lancet paper to pieces, showing that it was based on unsupported and fraudulent data provided by a small, relatively unknown private firm, that had somehow been involved in the trial. The reviewers of the journal had inexplicably accepted a paper full of flaws, without J o u r n a l P r e -p r o o f noticing that the results had been fabricated from non-existing data. The 182 scientists had written a strong letter to Lancet : as a result, the fraudulent paper had to be retracted by the journal, and by the authorsas well (32) , and WHO was forced to resume the trial. Understandably, the scandal had enormous worldwide resonance, which was reinforced by the fact that the results of a number of other less publicized trials on CQ and HCQ had appeared, or were about to appear, around the time of the WHO incident (10 at the end of July, 2020) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) . One of these studies (33) had concentrated on the problem of the dosages of HCQ, and had concluded that those used for the prevention of malaria were insufficient to inhibit or suppress the acute respiratory COVID-19 syndrome. Another (34) was an extension -by the same authors-of the original study by Gautret and coworkers (28) However, it wasn't so, since in the months that followed, happenings occurred that changed the picture, and resurrected the interest on CQ and HCQ. On August 19, 2020 were in the no-HCQ group. Both studies had found a significant decrease in the mortality risk (about 30% in the Italian study) in the participants treated with HCQ. These were very positive results, and had been supported by a correct statistical analysis, but a word of caution on them is necessary, since they had not been randomized.

However, the large number of patients involved certainly decreased the risk of errors.

J o u r n a l P r e -p r o o f 6 One last recent finding, coming from a different research line, could also be mentioned, as it offers a possible additional reason for the controversial findings the CQ-HCQ story has experienced and is still experiencing (45).

The penetration of the COVID-19 into target cells depends on the pH of endosomes, and CQ and HCQ inhibits it by raising it. However, as mentioned above, in some cell types the virus could also use a pH independent pathway for entry into cells . The penetration of COVID-19 into Vero (kidney) cells was found to be dependent on pH dependent proteases, whereas its penetration into Calu-3 cells (lung) depended instead on the pHindependent TMPRSS2 protease. However, if one looks at the matter in a dispassionated way, it is clear that the development of the CQ-HCQ story has had peculiar aspects. The initial enthusiasm triggered by the original observations, which had evident flaws, had certainly been generated by the desperate need to find a cure for the devastating disease. But it had been premature and exaggerated. A couple of general indications could perhaps still be extracted with caution from the data that are presently available in the super-abundant literature. The first is that at late stages of the infection HCQ is probably ineffective; the second has to do with the frequency and seriousness of the described adverse side effects of HCQ, which appear to have been grossly exaggerated . Sooner or later, anyway, the matter of CQ and HCQ must be brought back to the clean realm of science, where the rules of the scientific method , uncorrupted by emotional or ideological deviations, are the only possible option. The request seems reasonable also on theorethical grounds, as it is hard to understand how a drug, which has all the documented mechanisms of action expected of an agent that would successfully fight the virus, could instead be ineffective and even damaging. And it is also necessary to deal with the fact that doctors who see patients at home, or in hospitals at the initial stages of the infection, are generally convinced of the efficacy of HCQ, and defend its use, sometimes even emphatically. Possibly, if one would look at the very early early stages of the disease, the outlook could be different. In this vein, a brief discussion on CQ and HCQ as chemoprophylactic agents rather than as therapeutic means is thus in order.

As mentioned, CQ has been the most important therapeutic drug in the control of malaria, particularly of its resurgence after the international ban on dichloro-diphenyl-trichloroethane (DDT), which had practically eliminated the disease by exterminating the Anopheles mosquito. Unfortunately, the use of CQ had been compromised by the appearance of Plasmodium strains resistant to it because of a mutation in the pfcrt gene of the deadliest of them, P. Falciparum (46) .Thus, at the end of last century, several countries of Africa, where the malaria is an absolute tragedy, followed a recommendation of WHO and officially discontinued the use of CQ, replacing it with artemisinin. In spite of the official ban, CQ has nevertheless remained the most commonly used antimalarial drug even in the African countries in which the resistance to the Plasmodia had been very J o u r n a l P r e -p r o o f substantial. This has been so essentially because the resistance of P. falciparum to CQ rapidly declined, and its sensitivity to CQ re-emerged (47) . An accurate analysis of the household use of chloroquine in sub-Saharan Africa (48) has indeed shown that the consumption of CQ does not reflect the national policies of the African Countries, as it continues to be used at high rates in most of them. 

Hemoglobinmetabolism in the malaria parasite Plasmodium falciparum

Heme oxygenase: function, multiplicity, regulatory mechanisms, and cklinical applications

Malaria Pigment

Chloroquine: mechanism of drug action and resistance in Plasodium falciparum

On the molecular mechanism of chloroquine's antimalarial action

Chloroquine-induced inhibition of the production of TNF, but not of IL-6, is affected by the disruption of iron metabolism

Hydroxychloroquine: from malaria to autoimmunity

The anti-HIV 1 activity of chloroquine

The potential place of chloroquine in the treatment of HIV-1-infected patients

Anti-malarial drug chloroquine is highy effective in treating avian influenza A H5N1 virus infection in an animal model

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

Structural and molecular modeling studies reveal a new mechanism of action of chloroquine and hudroxychloroquine against SARS-CoV-2

Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents

Nabel, pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN

Hydroxychloroquine, a less toxicderivative of chloroquine , is effective in inhibiting SARS-Co-2 infection in vitro

Effect of lysosomotropic weak bases on infection of BHF-21 cells by Sindbis virus

Examination of potential inhibitors of Hepatitis A virus uncoating

Anti-HIV effects of chloroquine : mechanism of inhibition and spectrum of activity

Characterization of herpes simplex virus-containing organelles by subcellular fractionation: role of organelle acidification in assembly of infectious particles

The Cterminal domain of the MERS coronavirus Mprotein contains a trans-Golgi network localization signal

Chloroquine and hydroxychloroquine equally affect tumor necsis factor alpha, interleukin-6, and interferon-gamma production by peripheral blood mononuclear cells

Review of side effects and toxicity of chloroquine

Cardiac complications attributed tomchloroquine and hydroxychloroquine: a systematic review of the literature

Hydroxychloroquine retinopathy-implications of research advances for rheumatology care

Antiretroviral treatment

The Lancet, AIDS, the unbridgable gap

Hydroxychloroquineand azithromycin as a treatment of COVID-19: resultsof an open-label non-randomized trial

A rush to judgement ? Rapid reporting and dissemination of results and its consequences regarding thec use of hydroxychloroquine fr COVID-19

Review: hydroxychloroquine and chloroquine for treatmentof SARS-CoV-2 (COVID-19)

Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

Retraction-hydroxychloroquine or chloroquiunecwith or without a macrolide for trteatment of COVID-19: a multinational regiustry analysys

Finding the dose for Hydroxychloroquine prophylaxis for COVID-19: the desperate search for effectiveness

Clinical and microbiological effect of combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six -day follow up: a pilot ibservational study

A randomized trialmof hydroxychloroquine aspostexposure prophylaxis for COVID-19

Low dose of hydroxychloroquine reducesfatality of critically ill patientswith COVID-19, Sci China

Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State

Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061cases in Marseille, France

Observational study of hydroxychloroquine in hospitalizedpatients with COVID-19

No evidence of rapid antiviral clearance or clinical benefit with the combinaation of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection

Henry Ford COVID-19 Task Force,Treatment with hydroxychloroquine, axithromycin, and combination inn patients hospitalized with COVID-19, Intern

Use of hydroxychloroquine in hospitalized patients is associated with reduced mortality:Findings from the observational multicentre Italian CORIST study

Low-dose hydroxychloroquine therapy and mortalitynin hospitalized patients with COVID-19: A nationwide observational study on 8075 paricipants

Chloroquine does not inhibit infection ofv human lung cells with SARS-CoV-2

A molecular marker for chloroquine-resistant falciparum malaria

BCG vaccinatio policy and preventive chloroquine usage: do they have an impat on COVID-19 pandemic ?

Pattern of chloroquine use and resistance in sub-Saharan Africa: a systematic review of household survey and moleclar data

Hydroxychloroquinecprophylaxis for COVID-19 in India